摘要
Abstract
Objective:To investigate the clinical effect of Entacapone,Levodopa and Carbidopa Tablets combined with Levodopa and Benserazide Hydrochloride in patients with Parkinson's disease(PD).Method:A total of 80 PD patients from January 2021 to June 2024 who were admitted in Jinjiang Hospital were selected,and randomly divided into the control group(n=40)and the study group(n=40).The control group was treated with Levodopa and Benserazide Hydrochloride,and the study group was treated with Entacapone,Levodopa and Carbidopa Tablets combined with Levodopa and Benserazide Hydrochloride.The clinical efficacy,Parkinson's disease score,oxidative stress indicators,nerve factors,quality of life,adverse reactions in both groups were compared.Result:The total effective rate of the study group was 92.50%(37/40),higher than 75.00%(30/40)of the control group,the difference was statistically significant(P<0.05).After 12 weeks of treatment,the unified Parkinson's disease rating scale(UPDRS)scores of both groups were lower than those before treatment,and the study group was lower than that of the control group,the differences were statistically significant(P<0.05).After 12 weeks of treatment,the levels of glutathione peroxidase(GSH-Px)and glutathione(GSH)in two groups were higher than those before treatment,and those in study group were higher than those in control group,the differences were statistically significant(P<0.05).After 12 weeks of treatment,the levels of brain-derived neurotrophic factor(BDNF)and 5-hydroxytryptamine(5-HT)in both groups were higher than those before treatment,and the study group were higher than those of the control group,the differences were statistically significant(P<0.05).After 12 weeks of treatment,the 39-item Parkinson's disease questionnaire(PDQ-39)scores in both groups were lower than those before treatment,and the study group was lower than that of the control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The application of Entacapone,Levodopa and Carbidopa Tablets combined with Levodopa and Benserazide Hydrochloride in the treatment of PD patients can improve the clinical effect,improve the antioxidant and neuroprotective effects of patients,improve the quality of life,and have high safety.关键词
帕金森病/恩他卡朋双多巴片/多巴丝肼Key words
Parkinson's disease/Entacapone,Levodopa and Carbidopa Tablets/Levodopa and Benserazide Hydrochloride
